Vanguard Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.2M Sell
2,137,768
-73,665
-3% -$457K ﹤0.01% 2689
2026
Q2
$13.7M Buy
2,211,433
+46,582
+2% +$256K ﹤0.01% 2645
2026
Q1
$9.7M Buy
+2,164,851
New +$10.8M ﹤0.01% 2746

Other funds holding ABEO

Vanguard Capital Management's ABEO Position: Q3 2026 in Review

Vanguard Capital Management reduced its Abeona Therapeutics (ABEO) stake by 3.3% in Q3 2026, selling an estimated $457K and leaving 2,137,768 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

Vanguard Capital Management first reported a position in ABEO in Q1 2026 and has held it in 3 quarters since. The position peaked at $13.7M in Q2 2026. 115 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.

  • Vanguard Capital Management held 2,137,768 shares of Abeona Therapeutics worth $11.2M as of Q3 2026.
  • Vanguard Capital Management sold 73,665 Abeona Therapeutics shares in Q3 2026, an estimated $457K.
  • Abeona Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2689 holding.
  • Vanguard Capital Management first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Abeona Therapeutics position peaked at $13.7M in Q2 2026.
  • 115 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.